Alternative experimental models for biomedical research.
ILFARM is constantly looking for new bioactive molecules in leeches
Modern scientific research in the biomedical field heavily depends on the availability of appropriate animal models, whose fundamental contribution consists in the possibility of defining the cellular and molecular basis of several human pathologies, at the same time providing preclinical models to test potential drugs or innovative therapies in the same area.
The use of invertebrates (such as the leech Hirudo verbana) as experimental models in biomedical research is rapidly increasing due to their clear advantages over traditional models based on vertebrates, such as the house mouse or rat. In particular, the low cost and easy management of the reproduction protocols make medicinal leeches a reliable and favorable models, allowing a reduction in the cost of breeding and the relative purchase price for the final user.
Furthermore, the use of experimental models based on invertebrates is in line with the most recent European legislation on the use of animal models in biomedical research, based on the principle of the 3Rs (Replacement, Reduction, Refinement), introduced in order to minimize as much as possible the use of sentient animals in research protocols by substituting them with simpler animal models endowed with a less developed nervous system.
Basic research
The leech is an established alternative experimental model to vertebrates and is currently widely used in several biomedical research context, such as studies focused on:
- the mechanisms that regulate the immune response
- tissue regeneration and wound healing
- the functioning of the nervous system
- the environmental impact of different types of pollutants and nanomaterials deriving from human activities.
Research
biotechnology
The identification of new bioactive molecules produced by leeches is an expanding research field.
Indeed, leech-derived bioactive molecules with antibacterial, regenerative, antitumorali and pro- collagenic activity have been identified in the last decade, paving the way to the development of innovative therapeutic approaches for the treatment of lesions and bacterial infections at both a topical and systemic level.
This research fits perfectly into the funding programs allocated by the EU to address the dramatic emergency related to the issue of antibiotic resistance to an ever increasing number of pathogens (Action Plan 2021' of the 'Regional Foundation for Biomedical Research').
This problem is particularly serious in Italy, which is ranking first in Europe for the number of antibiotic resistance-related deaths: of the 33,000 deaths that occur in EU countries every year from infections caused by bacteria resistant to antibiotics, over 10,000 are in fact recorded in our country .